


IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re Application of:

James E. Galen

Appln. No.: 09/993,292

Filed: November 23, 2001



Docket No.: A8461

Conf. No.: 5386

Group Art Unit: 1645

Examiner: Duffy, P.

For: USE OF CLYA HEMOLYSIN FOR EXCRETION OF PROTEINS

STATEMENT TO SUPPORT FILING AND SUBMISSION IN  
ACCORDANCE WITH 37 C.F.R. §§ 1.821-1.825

MAIL STOP SEQUENCE

Commissioner for Patents  
P.O. Box 1450  
Alexandria, VA 22313-1450

Sir:

In connection with the substitute Sequence Listing submitted herewith, the undersigned hereby states that:

1. the submission, filed herewith in accordance with 37 C.F.R. §1.821(g), does not include any new matter;
2. the contents of the 26-page substitute Sequence Listing being filed in the present application, and the attached computer readable copy of the substitute Sequence Listing, submitted in accordance with 37 C.F.R. §1.821(c) and (e), respectively, are the same;
3. Applicant respectfully requests entry of the Sequence Listing into the application; and
4. all statements made herein of my own knowledge are true and that all statements made on information and belief are believed to be true, and further, that these statements were made with the knowledge that willful false statements and the like so made are punishable by fine or imprisonment, or both, under Section 1001 of Title 18 of the United States Code and that such willful false statements may jeopardize the validity of the application or any patent resulting therefrom.

Respectfully submitted,

Drew Hissong  
Registration No. 44,765

SUGHRUE MION, PLLC  
Telephone: (202) 293-7060  
Facsimile: (202) 293-7860

WASHINGTON OFFICE

23373

CUSTOMER NUMBER

Date: July 11, 2005